Skip to main content

TGTX

Stock

TGTX

Stock
Health Care
Biotechnology

Performance overview

TGTX Price
Price Chart

Forward-looking statistics

Beta
1.38
Risk
66.65%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

Company info

SectorHealth Care
IndustryBiotechnology
Employees270
Market cap$2.4B

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-1.0
Credit+8.2
Liquidity-0.2
Inflation-5.8
Commodities-0.8
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio36.63
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayNovember 4, 2024
Next dividend day—
Ex. dividend day—

News

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

Evercore ISI Senior Managing Director Julian Emanuel joins 'Closing Bell Overtime' to explain why he says now is the time to invest in small-caps.

CNBC Television (June 9, 2025)
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.

Benzinga (May 5, 2025)
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.

Zacks Investment Research (May 5, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free